Nouscom
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
€120MSeries D
ParticipantActivity from announced rounds
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
Develops and commercializes rare disease therapies using AI
Develops inhaled therapies for severe respiratory diseases